EUVIMEDEUVIMED entdecken
Systematische Übersicht

270 Incidence of Sarcopenia in Esophageal Cancer Patients Receiving Preoperative Neoadjuvant Therapy: A Systematic Review and Meta- Analysis

M Abosheisha, E Nasr, M Abdellatif, M Kandeel, A Alemam, A Asaad, M A S Hasan, M Alqasem, A Abdelaal, M Abdelglil, M Terra, A Swealem und 1 weitere

British Journal of Surgery · 10.07.2026 · 113 (Supplement_6)

DOI: 10.1093/bjs/znag063.014 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Surgery, online erschienen am 10.07.2026. Verfasst von M Abosheisha und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sarcopenia is a common and serious comorbidity in esophageal cancer patients undergoing neoadjuvant therapy (NAT). Treatment-related muscle loss has been linked to poorer postoperative recovery and reduced survival, yet reported incidence rates vary widely, and a clear synthesis of evidence is lacking.

Objective

To quantify the incidence of sarcopenia in esophageal cancer patients receiving preoperative NAT and evaluate its association with clinical outcomes.

Method

This systematic review and meta-analysis followed PRISMA 2020 guidelines and was registered on PROSPERO (CRD420251109294). PubMed, SCOPUS, Web of Science, and the Cochrane Library were searched for studies reporting sarcopenia in patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Random-effects models were used to estimate pooled incidence and outcome associations. Subgroup and sensitivity analyses addressed heterogeneity, and study quality was evaluated using the Newcastle Ottawa Scale.

Results

Twenty-six studies including 3,298 patients were identified. The pooled incidence of sarcopenia after NAT was 48% (95% CI: 38%–58%) with substantial heterogeneity (I² = 95.7%). Sarcopenia was significantly associated with poorer overall survival (HR: 2.10; 95% CI: 1.72–2.57), but was not significantly linked to recurrence-free survival or postoperative complications. Most studies were of moderate to high quality, though heterogeneity was influenced by differing diagnostic criteria and timing of assessment.

Conclusions

Sarcopenia is highly prevalent in esophageal cancer patients undergoing NAT and is strongly associated with increased mortality. It should be treated as a major, potentially modifiable complication. Standardized diagnostic criteria and early multimodal interventions particularly nutritional therapy and structured physical rehabilitation are urgently needed to improve outcomes in this vulnerable population.

Zitieren

APA

Abosheisha, M., Nasr, E., Abdellatif, M., Kandeel, M., Alemam, A., Asaad, A., Hasan, M. A. S., Alqasem, M., Abdelaal, A., Abdelglil, M., Terra, M., Swealem, A., & Ismaiel, M. (2026). 270 Incidence of Sarcopenia in Esophageal Cancer Patients Receiving Preoperative Neoadjuvant Therapy: A Systematic Review and Meta- Analysis. British Journal of Surgery, 113(Supplement_6). https://doi.org/10.1093/bjs/znag063.014

Vancouver

Abosheisha M, Nasr E, Abdellatif M, Kandeel M, Alemam A, Asaad A, et al. 270 Incidence of Sarcopenia in Esophageal Cancer Patients Receiving Preoperative Neoadjuvant Therapy: A Systematic Review and Meta- Analysis. British Journal of Surgery. 2026;113(Supplement_6). doi:10.1093/bjs/znag063.014

BibTeX
@article{Abosheisha2026,
  author = {Abosheisha, M and Nasr, E and Abdellatif, M and Kandeel, M and Alemam, A and Asaad, A and Hasan, M A S and Alqasem, M and Abdelaal, A and Abdelglil, M and Terra, M and Swealem, A and Ismaiel, M},
  title = {270 Incidence of Sarcopenia in Esophageal Cancer Patients Receiving Preoperative Neoadjuvant Therapy: A Systematic Review and Meta- Analysis},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_6},
  doi = {10.1093/bjs/znag063.014}
}
Kostenlos starten →